Eisai submits EMA application of in-house developed lenvatinib for renal cell carcinoma

The number of patients with renal cancer in Europe is estimated to be 115,000,1 and renal cell carcinoma comprises more than 90% of all malignancies of the kidney.2 For advanced or metastatic renal cell carcinoma that is difficult to treat with surgery, the standard treatment method is molecular targeted drug therapy, however with low 5-year survival rates, this remains a disease with significant unmet medical need.01/12/2016
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news